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The acute neural effects of progesterone are mediated by its neuroactive metabolites
allopregnanolone and pregnanolone. These neurosteroids potentiate the inhibitory actions
of c-aminobutyric acid (GABA). Progesterone is known to produce anxiolytic effects in
animals, but recent animal studies suggest that pregnanolone increases anxiety after a period
of low allopregnanolone concentration. This effect is potentially mediated by the amygdala and
related to the negative mood symptoms in humans that are observed during increased
allopregnanolone levels. Therefore, we investigated with functional magnetic resonance
imaging (MRI) whether a single progesterone administration to healthy young women in their
follicular phase modulates the amygdala response to salient, biologically relevant stimuli. The
progesterone administration increased the plasma concentrations of progesterone and
allopregnanolone to levels that are reached during the luteal phase and early pregnancy.
The imaging results show that progesterone selectively increased amygdala reactivity.
Furthermore, functional connectivity analyses indicate that progesterone modulated func-
tional coupling of the amygdala with distant brain regions. These results reveal a neural
mechanism by which progesterone may mediate adverse effects on anxiety and mood.
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Introduction
Changes in the blood concentration levels of proges-
terone and estradiol are associated with changes in
mood regulation1 and cognition.2 For instance, ex-
plicit memory3–5 and mood4–6 deteriorate during
pregnancy when progesterone and estradiol levels
reach their highest physiological concentrations.
Mood is also influenced by the more subtle changes
in these hormone levels during the menstrual cycle.
The negative mood symptoms in premenstrual dys-
phoric disorder (PMDD) and premenstrual syndrome
(PMS) occur during the luteal phase, when proges-
terone and estradiol concentrations are high, and
disappear a few days after the onset of menstruation,
when these hormone concentrations are lowest.7
However, these negative mood symptoms develop in
the absence of abnormal gonadal steroid hormone
concentrations.7,8 Furthermore, the administration of
progesterone or estradiol after gonadal hormone
suppression produces negative mood symptoms in
women with PMS, but not in those without PMS.9
The negative mood in PMDD/PMS therefore appears
as an abnormal response to normal hormonal
changes.10 The neural mechanism by which these
hormones influence mood are, however, unknown.
Animal research has shown that progesterone
modulates anxiety, and that these effects are probably
mediated by its metabolite allopregnanolone.11–13
This neurosteroid potentiates the inhibitory actions
of g-aminobutyric acid (GABA) by modulation of the
GABAA receptor.
14 Consistent with this GABAergic
mechanism, progesterone and allopregnanolone ad-
ministration usually produce an anxiolytic effect11,13
by the action on the amygdala.15 Also pregnanolone,
the less potent 5b stereoisomer of allopregnanolone
that has a similar effect,16,17 can produce anxiolysis.18
However, it induces anxiogenic effects to aversive
stimuli after a period of relative allopregnanolone
suppression,18 which mimics the low allopregnano-
lone levels during the human follicular phase.19 As
the amygdala is involved in a wide range of emotional
behavior, and local infusions of GABA antagonists
induce anxiogenic effects,20 the amygdala may
mediate the anxiogenic effects of allopregnanolone
as well.
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In the present study, we investigated whether a
single progesterone administration to healthy women
during their follicular phase increases amygdala
reactivity. The amygdala is part of a larger emotion
circuitry, which is important for the identification of
the emotional significance of stimuli, the generation
of an affective response and emotion regulation.21 We
therefore explored whether progesterone’s modula-
tion of amygdala activity influences the functional
integration of this system. We used an oral adminis-
tration of micronized progesterone, which increases
allopregnanolone and pregnanolone concentrations
to a similar extent.22 By administering progesterone
instead of comparing neural activity during the luteal
(high progesterone and estradiol) and the follicular
phases (low progesterone and estradiol), the results of
this study provide a mechanistic account for a
hormone–brain interaction that is not confounded
by (spurious) effects linked to the menstrual cycle.
Materials and methods
Subjects
Eighteen naturally cycling women (mean age 24
years; range: 19–39) participated in this study after
signing informed consent. They were healthy as
determined by routine physical and laboratory exam-
inations, and had no current psychiatric disorder
indicated by a structured interview.23 They were
right-handed, free of medication, did not use
hormonal contraceptives and reported no history of
psychiatric or somatic disease potentially affect-
ing the brain. This study was approved by the local
ethics committee (CMO Regio Arnhem-Nijmegen,
The Netherlands).
Design and procedure
The subjects participated twice during the early
follicular phase (days 2–7) of different menstrual
cycles, when endogenous hormone levels are low.
They arrived at B0815 hours after overnight fast to
receive a standardized light breakfast, after which
400 mg of micronized progesterone or placebo was
administered orally, in a double-blind, crossover
fashion. A venous blood sample was collected before
drug administration and the scanning session, which
startedB90 min after drug intake. In addition, subjects
completed a mood rating questionnaire (MRS)24 just
before scanning and a state anxiety questionnaire
(STAI)25 about 190 min after drug intake.
Behavioral task
The experimental paradigm consisted of a blocked
design, including an emotion condition and a visuo-
motor control condition. This paradigm has been
used previously to investigate drug effects on amyg-
dala reactivity.26,27 It robustly engages the amygdala,
by contrasting the response to simultaneously pre-
sented angry and fearful face stimuli (http://
www.macbrain.org) with the response to ellipses (that
consisted of scrambles of the same face stimuli). The
results therefore do not show emotion-specific effects,
but rather a general response to salient, biologically
relevant stimuli.
Two emotion blocks were interleaved with three
control blocks, and each 30-s block consisted of six
5-s trials. Each trial consisted of three simultaneously
presented stimuli, with the cue stimulus presented
above the target and distractor (see Hariri et al.26). In
the emotion condition, an angry or fearful face was
presented on top as cue, and subjects had to indicate
by an appropriate button press which of the bottom
two faces (one angry and one fearful) matched the cue
in emotional expression. The three simultaneously
presented faces per trial were from different persons
from the same sex. Half the trials presented faces of
men and half of women, half of each target emotion
(angry or fearful). In the control condition, a horizon-
tally or vertically oriented ellipse was presented as
cue above two ellipses (one vertical and one hori-
zontal), and subjects had to select the identically
oriented ellipse.
Data acquisition
Scanning was performed with a 1.5 T Siemens Sonata
MR scanner (Siemens, Erlangen, Germany), equipped
with a standard head coil. Seventy-six T2*-weighted
EPI-BOLD images were acquired per subject with an
echo time of 30 ms to reduce signal dropout, with
each image volume consisting of 33 axial slices
(3 mm, 0.5 mm slice gap, TR = 2.290 s, 64 64 matrix,
FOV = 224 mm, FA = 901). In addition, a high-resolu-
tion T1-weighted structural MR image was acquired
for spatial normalization procedures (MP-RAGE,
TR = 2250 ms, TE = 3.93 ms, 176 contiguous 1 mm
slices, 256 256 matrix, FOV = 256 mm).
fMRI data analysis
Image analysis was performed with SPM2 (Wellcome
Department of Imaging Neuroscience, London, UK).
The first five EPI volumes were discarded to allow
for T1 equilibration, and the remaining images
were realigned to the first volume. Images were
then corrected for differences in slice acquisition
time, spatially normalized to the Montreal Neuro-
logical Institute T1 template, super-sampled into
2 22 mm3 voxels, and spatially smoothed with a
Gaussian kernel of 10 mm FWHM.
Statistical analysis was performed within the
framework of the general linear model.28 For each
drug condition, the two experimental conditions were
modeled as box-car regressors convolved with the
canonical hemodynamic response function of SPM2.
In addition, the realignment parameters were in-
cluded to model potential movement artefacts as well
as a high-pass filter (cutoff at 1/128 Hz). To account
for various global effects, the EPI data were pro-
portionally scaled. Temporal autocorrelation was
modeled with an AR(1) process and the parameter
estimates were obtained by maximum likelihood
estimation29 to allow departures from sphericity.
Single–subject parameter images contrasting the
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emotion and control conditions were obtained and
entered into subsequent random effects analyses.
The main effect of the task was assessed with a one-
sample t-test, and the effect of drug (that is, drug
task interaction) was assessed with a paired t-test. In
addition, the effects of drug on the functional
integration of the amygdala was investigated using a
functional connectivity analysis.30 The time course of
amygdala activity was extracted (that is, the first
eigenvariate of a sphere with 6 mm radius around the
peak voxel of the right amygdala as identified by the
main effect of task), and added as a covariate of
interest to the model. Single-subject parameter images
containing the regression coefficients were obtained
and entered into subsequent random effects analyses.
One-sample t-tests were used to identify brain regions
with a correlated time course, and paired t-tests were
used to identify the effects of drug on functional
connectivity with amygdala. Statistical tests were
family-wise error (FWE) rate corrected for multiple
comparisons across the whole brain or the region-of-
interest (ROI), using a small volume correction,31
unless stated otherwise. The bilateral amygdala ROI
was anatomically defined using the WFU Pickatlas,32
and the bilateral face responsive regions in the
fusiform gyri were defined as spheres with 14 mm
radius around previously reported Talairach coordi-
nates33 that were transformed into MNI-space (http://
imaging.mrc-cbu.cam.ac.uk/imaging/MniTalairach).
Furthermore, mean amygdala activity in both drug
conditions was extracted from the bilateral amygdala
ROI for additional correlation analyses.34
Serum analysis
Progesterone was measured with Delfia progesterone
kits (Wallac Oy, Turku, Finland) according to the
manufacturer’s instructions. Allopregnanolone was
measured with radioimmunoassay (RIA) after diethy-
lether extraction and celite chromatography (recovery
78%). The antiserum was directed against 3a-hydro-
xy-20-oxo-5a-pregnan-11-yl carboxymethyl ether-BSA
with low cross reactivity and a gift from Dr Robert H
Purdy (Department of Psychiatry, College of Medi-
cine, University of California, San Diego, CA, USA).
The intra-assay coefficient of variation was 6.5% and
inter-assay coefficient of variation of was 8.5%.35
Results
The baseline plasma concentrations of progesterone
and allopregnanolone did not differ significantly
between the progesterone and placebo condition
(both P > 0.2). The progesterone administration in-
creased the progesterone concentration from the
follicular to the luteal phase range (mean7s.e.m.,
from 1.9470.29 to 16.8376.17 nmol/l, t(16) = 2.39,
P = 0.03), and increased the concentration of allo-
pregnanolone from 0.6070.05 to 24.9877.30 nmol/l
(t(16) = 3.35, P = 0.004). This allopregnanolone level is
similar to that during early pregnancy.36,37 However,
progesterone had no significant effect on the mood24
or state anxiety25 questionnaires (all P > 0.2) and did
not significantly modulate response accuracy or
reaction times in the behavioral task (all P > 0.05).
These factors therefore appear to have little explana-
tory value in relation to the observed differences in
brain activity between the progesterone and placebo
conditions.
The functional magnetic resonance imaging (fMRI)
results show that the emotion condition yielded
larger responses than the control condition in the
amygdala, ventral visual stream (ranging from the
primary visual cortex to the fusiform gyrus), inferior
frontal gyri, cerebellar vermis and supplementary
motor area (P < 0.05, corrected; see Table 1 and Figure
1). Critically, progesterone increased the right amyg-
dala response (P < 0.05, corrected; see Table 1 and
Figures 2 and 3). A similar effect was also present in
the left amygdala, although at a less conservative
threshold (see Table 1). In contrast, progesterone did
not significantly influence neural activity in other
brain areas.
To explore the relation between amygdala reactivity
and allopregnanolone levels, state anxiety and mood
across subjects, additional correlation analyses were
performed. While progesterone reliably increased
amygdala reactivity in the within-subjects compar-
ison, no significant correlations between allopregna-
nolone levels and amygdala activity were observed
across subjects during the progesterone or placebo
conditions. However, progesterone modulated the
relation between amygdala activity and mood. While
amygdala activity was positively correlated with the
MRS subscales alertness (r = 0.66, P = 0.003) and
contentedness (r = 0.53, P = 0.025) during the placebo
condition, no such relation was observed during the
progesterone condition (P > 0.1).
The functional connectivity analysis identified
various brain regions that were functionally coupled
with the right amygdala. Brain regions with a positive
correlation with amygdala activity included regions
in the medial temporal lobe (including the left
amygdala and both hippocampi), the basal ganglia,
orbitofrontal cortex, temporal pole, thalamus, inferior
temporal gyri, pons and fusiform gyri. Brain regions
in the midbrain and cerebellar vermis showed a
negative correlation with amygdala activity (P < 0.05,
corrected; see Table 2).
Progesterone decreased functional connectivity of
the fusiform gyrus with the amygdala (P < 0.05,
corrected). Furthermore, the results indicate that
progesterone increased functional connectivity of
the dorsal anterior cingulate cortex with the amygdala
at a less conservative threshold (P < 0.001, uncor-
rected; see Table 2 and Figure 4).
Discussion
The results show that a single progesterone adminis-
tration to healthy women in their follicular phase
selectively increases amygdala reactivity. The pro-
gesterone administration significantly increased the
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plasma concentration of progesterone as well as that
of its metabolite allopregnanolone, which potentiates
the inhibitory actions of GABA.14 Because it is this
neurosteroid that mediates the acute effects of
progesterone,11,13 the observed activity increase of
amygdala is probably mediated by the neuroactive
metabolites allopregnanolone and/or pregnanolone.
The amygdala is critically involved in a wide range
of emotional behavior,38 including fear and anxiety,20
and it displays a pathological pattern of responsive-
ness in certain anxiety39 and mood disorders.40 A
previous animal study, in which a relatively large
dose of allopregnanolone was infused into the central
nucleus of the amygdala, has shown that allopregna-
nolone acts on amygdala to mediate anxiolysis.15
Although the present study does not show an
anxiogenic effect of allopregnanolone, the results
suggest a neural mechanism by which allopregnano-
lone could increase anxiety and worsen mood (that is,
by increasing amygdala activity).
Progesterone decreased functional connectivity of
the amygdala with the fusiform gyrus, a brain region
preferentially involved in the processing of faces.33,41
The amygdala projects back to all levels of the ventral
visual stream,42 and it influences activity in this brain
Table 1 Cluster maxima for brain regions with a larger response during the emotion than the control condition (main effect of
task), and for brain regions that are modulated by progesterone (drug task interaction)
MNI coordinates Cluster size t P-valuea
x y z
Main effect of task
Right inferior occipital and temporal cortex 26 90 10 3613 17.9 < 0.001
Left inferior occipital and temporal cortex 26 92 12 3138 14.1 < 0.001
Right amygdala 22 4 16 125 9.0 < 0.001
Left amygdala 22 10 16 164 8.5 < 0.001
Right inferior frontal gyrus 44 10 32 575 8.4 < 0.001
Left inferior frontal gyrus 44 10 28 240 8.4 < 0.001
Cerebellar vermis 2 74 32 63 7.0 0.002
Supplementary motor area 0 10 60 41 6.9 0.002
Left inferior frontal gyrus 56 22 4 22 6.7 0.005
Drug task interaction (progesterone > placebo)
Right amygdala 26 6 22 14 5.8 0.001b
Left amygdala 28 6 22 — 2.9 0.005c
aP-values are corrected for multiple comparisons across the whole brain (P < 0.05, kX10).
bP-value corrected for multiple comparisons across the amygdala (P < 0.05).
cPeak voxel (P-value is uncorrected for multiple comparisons).
Figure 1 Larger amygdala responses to salient, biologically
relevant stimuli than the control condition in the placebo
(a) and the progesterone condition (b). The sagittal slices on
the left (x = 26) and the maximum intensity projections on
the right are thresholded at P < 0.001, uncorrected for
multiple comparisons.
Figure 2 A single progesterone administration increases
the amygdala response. A coronal slice (a) shows the
increased right amygdala reactivity (y =6) in the proges-
terone condition. The maximum intensity projection (b)
shows the selectivity of the effect. The figures are
thresholded at P < 0.001, uncorrected for multiple compar-
isons. Note that the same effect was observed in the left
amygdala at a less conservative statistical threshold.
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region during face perception,43 suggesting that
progesterone decreases the back projections of the
amygdala to the fusiform gyrus. However, because
functional connectivity is a correlational method, this
result may also reflect the influence of the fusiform
gyrus on the amygdala by feed-forward projections.
Furthermore, although the functional integration of
the emotion circuitry with the amygdala was largely
unaltered by progesterone, the results indicate that
progesterone increased functional coupling of the
dorsal anterior cingulate gyrus (dACC) with the
amygdala. The dACC is activated during the cognitive
evaluation of threatening stimuli which reduces
amygdala activity,44 and is thought to support the
Figure 3 Mean (7s.e.m.) amygdala reactivity in the
progesterone and placebo condition (26, –6 , –22).
Table 2 Cluster maxima for brain regions that are functionally connected with the right amygdala, and for brain regions whose
connectivity shows an interaction with progesterone
MNI coordinates Cluster size t P-valuea
x y z
Positive correlation
MTL, basal ganglia, OFC, temporal pole, thalamus 24 0 16 14 025 18.8 < 0.001
Right inferior temporal gyrus 62 54 8 98 8.6 < 0.001
Right inferior occipital gyrus 40 88 2 82 7.6 0.001
Pons 12 32 42 479 7.1 0.002
Left inferior temporal gyrus 52 64 8 39 6.3 0.012
Left middle temporal gyrus 62 46 8 10 6.0 0.026
Left fusiform gyrus 48 64 10 93 5.5 0.001b
Right fusiform gyrus 52 58 10 56 5.1 0.002b
Negative correlation
Midbrain 4 26 14 151 8.2 < 0.001
Cerebellar vermis 0 52 12 57 5.4 0.003
Progesterone > placebo
Anterior cingulate cortex 10 24 40 9 4.7 < 0.001c
Placebo > progesterone
Right fusiform gyrus 42 60 6 10 5.5 0.010b
MTL, medial temporal lobe; OFC, orbitofrontal cortex.
aP-values are corrected for multiple comparisons across the whole brain (P < 0.05, kX10).
bP-values corrected for multiple comparisons across the region-of-interest (P < 0.05).
cP-value uncorrected for multiple comparisons (P < 0.001).
Figure 4 Progesterone modulates functional connectivity
of the (a) dorsal anterior cingulate cortex (10, 24, 40) and
(b) right fusiform gyrus (42, –60, –6) with the amygdala
(mean7s.e.m.).
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cognitive control of emotion (that is, reappraisal).45
This suggests either a progesterone-induced change in
dACC regulation of amygdala activity, or conversely,
the influence of the amygdala on regulatory pro-
cesses. However, this result should be interpreted
with caution, because the effect did not remain
significant after correction for multiple comparisons.
Although progesterone consistently increased
amygdala reactivity in a within-subject comparison,
no significant correlations between allopregnanolone
levels and amygdala activity were observed across
subjects. However, serum allopregnanolone levels do
not reflect the (regionally specific) availability of this
and other neuroactive metabolites in the brain, and
individual differences in neurosteroid sensitivity may
obscure a relation between neurosteroid levels and
amygdala reactivity when assessed across indivi-
duals. Furthermore, while amygdala activity was
positively correlated to alertness and contentedness
in the placebo condition, which are two subscales of
the mood-rating scale that was used, no correlations
with state anxiety and mood were observed in the
progesterone condition. The absence of a relation
between amygdala reactivity and state anxiety and
mood in the progesterone condition could reflect
the limitation of this study to assess across-subject
correlations, because the study was designed as a
within-subjects investigation. In addition, the effects
of progesterone on mood are probably mediated
by interactions within a larger emotion circuitry.46
The absence of a large change in the functional
integration of the emotion circuitry may, therefore,
explain the absence of a significant change in mood
or anxiety.
Two related mechanisms could explain the para-
doxical allopregnanolone-induced amygdala activity
increase. First, the hormonal milieu appears to
determine the acute effects of the neuroactive proges-
terone metabolites. A study in female mice showed
that an otherwise anxiolytic dose of pregnanolone
increases anxiety to an aversive stimulus after a
period of relative allopregnanolone suppression,
which was accomplished by administering a 5a-
reductase inhibitor for 3 days that attenuates the
metabolic transformation of progesterone to allopreg-
nanolone.18 This approach was used to mimic the
prolonged low allopregnanolone concentration dur-
ing the human follicular phase,19 the menstrual cycle
phase during which the women in this study were
investigated.
Second, allopregnanolone induces a nonlinear
behavioral response.47–49 Low doses of allopregnano-
lone increase aggressive behavior in mice, whereas
higher doses decrease aggression.50 Moreover, the
addition of a low dose of progesterone to the
treatment with estradiol during hormonal replace-
ment therapy increases negative mood, but higher
doses do not.51 These negative mood symptoms are
related to allopregnanolone levels in a bimodal
fashion, as these symptoms are only present at
moderate, but not low or high allopregnanolone
concentrations.35,51 Furthermore, allopregnanolone
levels are lower in PMS patients that respond to
antidepressant or placebo treatment than nonrespon-
ders.52 In the present study, an increased responsive-
ness of the amygdala was observed after increasing
the progesterone and the allopregnanolone concen-
trations from the follicular phase to levels that are
naturally occurring during the luteal phase and early
pregnancy, respectively.36,37 The increased amygdala
response might therefore be specific for this con-
centration change, while higher supraphysiological
concentrations might eventually decrease amygdala
activity,15 in parallel with increased sedation in
humans.53 These results therefore show that changes
in progesterone level that are within the physiological
range can increase amygdala activity.
These two mechanisms are not mutually exclusive
but may interact, because the probable progesterone
dose-dependent amygdala response is probably modu-
lated by the hormonal milieu. In this context, it is
important to note that during natural hormone fluctua-
tions during the menstrual cycle, high progesterone
levels occur only in the presence of increased estradiol
levels. Thus, the threshold for amygdala reactivity
probably changes over the menstrual cycle. This
suggestion is supported by studies showing that the
response of healthy women to a pregnanolone dose is
larger in the luteal than the follicular phase.54 Further-
more, women with PMS experience more severe
symptoms during cycles with high luteal phase
progesterone and estradiol levels,55 and higher estrogen
doses increase negative mood symptoms during the
progestin phase of hormonal replacement therapy.56
The mechanism by which allopregnanolone could
increase amygdala activity is not well understood.
However, the paradoxical allopregnanolone-induced
amygdala activity increase could reflect the disin-
hibition of the principal neurons of the amygdala via
inhibition of the inhibitory interneurons,49 a mechan-
ism that has been demonstrated for the disinhibitory
actions of dopamine.57 Neurosteroid action is brain
region and neuron-specific, and neurons of the
central nucleus of the amygdala appear relatively
insensitive to allopregnanolone.58 This heterogeneity
in neurosteroid sensitivity could be mediated by
regional differences in receptor subunit composition,
phosphorylation and steroid metabolism.58 Specifi-
cally, allopregnanolone inhibits the a4b2d GABAA
receptor, which reduces tonic inhibition and thereby
increases excitability. Because this receptor is highly
sensitive to neurosteroids, inhibition of this receptor
at relatively low neurosteroid concentrations can
induce paradoxical effects,59 and may contribute to
amygdala disinhibition.
The amygdala has many (largely reciprocal) con-
nections to brain areas that are involved in sensory
processing, visceral functioning, emotional behavior
and mood.60 The progesterone-induced amygdala
activity increase could therefore affect the processing
in many other brain regions relevant for mood
regulation. Studies with depressed patients suggest
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that negative mood is generated by increased activity
of brain structures that support the identification of
the emotional significance of stimuli and the gene-
ration of an affective response (for example, the
amygdala, insula, ventral striatum and ventral pre-
frontal cortex), and decreased activity of brain
structures supporting emotion regulation (for exam-
ple, the dorsal prefrontal cortex and hippocampus).61
The menstrual cycle has been shown to modulate
activity in several of these brain regions,62–65 suggest-
ing that progesterone and estradiol may influence
mood by modulating this emotion circuitry. The
results of the present study show that progesterone
increases amygdala activity and indicate that it
increases functional coupling with the dACC, without
affecting the response amplitude in other brain
regions. The results of our study therefore suggest
that progesterone and/or allopregnanolone modulates
amygdala activity, and may, thereby, change the
functionality of a larger emotion circuitry.
The amygdala is involved in a wide range of
emotional behavior, including social cognition66 and
the stress response,67 which appears to be modulated
by progesterone. For example, the modulation of the
preference for faces during the menstrual cycle
appears to be mediated by progesterone,68,69 as well
as the enhancement of the hypothalamus–pituitary–
adrenal (HPA) axis response to stressors during the
luteal phase.70,71 Our results suggest that progesterone
could modulate these processes by increasing the
responsiveness of the amygdala.
The present study shows that allopregnanolone
can have paradoxical effects on amygdala activity in
healthy women, without influencing anxiety or mood.
However, this mechanism could mediate the negative
effects of allopregnanolone on anxiety and mood in
susceptible women. Whereas the administration of
progesterone or estradiol after gonadal hormone
suppression does not produce mood changes in
healthy women, it produces negative mood symptoms
in women with PMS.9 Furthermore, PMS patients
have a different sensitivity to pregnanolone during
the high progesterone luteal phase,54 suggesting
that allopregnanolone could affect amygdala activity
differently in patients with PMDD/PMS. Because
the amygdala is pathologically activated in certain
anxiety39 and mood disorders,40 we speculate that
allopregnanolone might increase amygdala activity to
a larger extent in women with PMDD/PMS than in
healthy women as observed in this study, which
could explain part of the negative mood symptoms in
PMDD/PMS and possibly other gonadal hormone-
related mood disorders.
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